Does Connexin 43 gene therapy prevent persistent atrial fibrillation in a porcine model?
Connexin 43 gene therapy shows potential as a viable strategy for preventing atrial arrhythmias based on preclinical porcine data.
Our results highlight the contribution of Cx43 to the pathophysiology of AF and demonstrate the viability of gene therapy for prevention of atrial arrhythmias.
Bikou et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: